New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
08:57 EDTOMED, BAYRYOncoMed commences third Phase 1b clinical trial for OMP-54F28
OncoMed Pharmaceuticals (OMED) announced the initiation of patient treatment for its third multi-center Phase 1b clinical trial of OMP-54F28 with carboplatin and paclitaxel in patients with platinum-sensitive ovarian cancer. OMP-54F28 is a first-in-class decoy receptor targeting the Wnt pathway and is part of OncoMed's collaboration with Bayer Pharma AG (BAYRY). The Phase 1b clinical trial of OMP-54F28 in combination with carboplatin and paclitaxel is a dose-escalation study in patients with recurrent platinum-sensitive ovarian cancer. Primary objectives of the trial are to evaluate safety of this combination regimen and determine a recommended Phase 2 dose for OMP-54F28 in combination with carboplatin and paclitaxel. Key secondary and exploratory objectives include evaluation of the pharmacokinetics and pharmacodynamics of OMP-54F28, as well as the efficacy of this combination. Tumor tissue from patients will be used to explore predictive biomarker hypotheses related to the efficacy of OMP-54F28.
News For OMED;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
07:30 EDTBAYRYZoetis takeover 'highly probable' event in 2015, says Jefferies
Jefferies sees a potential acquisition of Zoetis (ZTS) by another industry player like Bayer (BAYRY) as a "highly probable" event during 2015. The firm raised its price target for Zoetis shares to $53 from $46 and believes the company's 2015 guidance, while missing expectations, leaves room for upside. It keeps a Buy rating on the stock.
November 25, 2014
10:53 EDTBAYRYGMO seed makers limit launches as China slow on approvals, Reuters says
Seed companies like Syngenta (SYT), Dow AgroSciences (DOW) and Bayer (BAYRY) are altering their plans for new product launches as China has taken longer than usual to approve new GMO crops, says Reuters. Grain traders Cargill and Archer Daniels Midland (ADM) have already sued Syngenta, claiming the seed company misrepresented how long it would take to win Chinese approval for the seeds, added Reuters. Monsanto (MON) is another company in the seed business. Reference Link
10:00 EDTBAYRYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3M Company (MMM) initiated with an Underperform at RBC Capital... Ametek (AME) initiated with an Outperform at RBC Capital... AstraZeneca (AZN) initiated with an Outperform at Exane BNP Paribas... Bayer (BAYRY) initiated with a Neutral at Exane BNP Paribas... Carlisle (CSL) initiated with a Sector Perform at RBC Capital... Colfax (CFX) initiated with a Sector Perform at RBC Capital... Dover (DOV) initiated with a Sector Perform at RBC Capital... Eaton (ETN) initiated with a Sector Perform at RBC Capital... Emerson (EMR) initiated with a Sector Perform at RBC Capital... Evercore Partners (EVR) initiated with an Outperform at Macquarie... Fifth Street Asset (FSAM) initiated with a Buy at MLV & Co.... Flowserve (FLS) initiated with an Underperform at RBC Capital... General Electric (GE) initiated with an Outperform at RBC Capital... GlaxoSmithKline (GSK) initiated with an Underperform at Exane BNP Paribas... Grainger (GWW) initiated with a Sector Perform at RBC Capital... Hanesbrands (HBI) initiated with a Buy at UBS... Hercules Technology (HTGC) initiated with a Neutral at Macquarie... HomeStreet (HMST) initiated with a Neutral at Macquarie... Honeywell (HON) initiated with an Outperform at RBC Capital... IDEX Corp. (IEX) initiated with an Outperform at RBC Capital... Illinois Tool Works (ITW) initiated with a Sector Perform at RBC Capital... Ingersoll-Rand (IR) initiated with a Sector Perform at RBC Capital... ManTech (MANT) initiated with a Buy at Maxim... Novartis (NVS) initiated with an Outperform at Exane BNP Paribas... Nu Skin (NUS) initiated with a Neutral at Citigroup... Oppenheimer Holdings (OPY) initiated with a Neutral at Macquarie... Pentair (PNR) initiated with an Outperform at RBC Capital... Raymond James (RJF) initiated with a Neutral at Macquarie... Roche (RHHBY) initiated with an Outperform at Exane BNP Paribas... Roper Industries (ROP) initiated with an Outperform at RBC Capital... SPX Corp. (SPW) initiated with a Sector Perform at RBC Capital... Sanofi (SNY) initiated with an Outperform at Exane BNP Paribas... Tyco (TYC) initiated with an Outperform at RBC Capital... United Technologies (UTX) initiated with an Outperform at RBC Capital... WESCO (WCC) initiated with an Outperform at RBC Capital... Xylem (XYL) initiated with a Sector Perform at RBC Capital.
05:27 EDTBAYRYBayer initiated with a Neutral at Exane BNP Paribas
November 24, 2014
15:53 EDTBAYRYBayer working with Credit Suisse to explore diabetes unit sale, Bloomberg says
Subscribe for More Information
15:38 EDTBAYRYBayer considering sale of diabetes unit for up to $2.5B, Bloomberg reports
10:14 EDTBAYRYFDA grants QIDP designation to Bayer's Amikacin Inhale, Ciprofloxacin DPI
Subscribe for More Information
07:57 EDTBAYRYPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
November 21, 2014
08:17 EDTOMEDOncoMed presents data from tarextumab, demcizumab trials
OncoMed Pharmaceuticals presented data in two posters highlighting the company's translational research and biomarker efforts for its tarextumab and demcizumab clinical programs Jakob Dupont, M.D., OncoMed's Chief Medical Officer, stated, "The data from the Phase 1b clinical trials of tarextumab and demcizumab demonstrate that our preclinical understanding of on-target drug activity and predictive biomarkers is being validated in the clinic as we study actual patient tumor samples. In the ALPINE Phase 1b study in advanced pancreatic cancer, we see clear evidence that tarextumab modulates the Notch cancer stem cell pathway in patient samples and that there is a potential association between tumors that show higher levels of Notch3 gene expression and best responses to tarextumab treatment. In the demcizumab poster presentation, a case study is described from our Phase 1b trial in pancreatic cancer in which the tumor response to treatment that occurred in the clinic correlates with what we observe using patient-derived xenograft models. This may provide insights into the development of potential biomarkers of response to demcizumab treatment in that program."
November 20, 2014
08:36 EDTBAYRYZoetis guidance positive, says BMO Capital
Subscribe for More Information
November 19, 2014
07:54 EDTOMEDOncoMed presents biomarker-focused clinical data from Anti-Notch1 Phase 1a trial
Subscribe for More Information
November 18, 2014
05:43 EDTBAYRYRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information
November 14, 2014
07:14 EDTBAYRYAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
09:33 EDTBAYRYZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use